Ramelteon ameliorates abnormal sleep-wake behavior in a zebrafish model of Parkinson’s disease by facilitating abnormal lipid metabolism
Objective: The study aims to explore the role of melatonin receptor 1 (MT1) in the regulation of sleep-wake behavior in rotenone-induced Parkinson's disease (PD) model…Angiotensin II Type 1 (AT1) receptor antagonists as potential candidates for anxiety treatment in Parkinson’s Disease
Objective: The aim of this study was to explore the effects of Angiotensin II Type 1 receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) on…LRRK2 kinase activity regulates sphingolipid hydrolase enzymatic activities in different cell lines: induced pluripotent stem cell-derived dopaminergic neurons, primary monocyte‐derived macrophages and SH-SY5Y
Objective: To assess whether inhibition of the kinase activity of LRRK2 affects changes in enzyme activity of sphingolipid hydrolase in the culture of dopaminergic neurons…Orthostatic hypotension and frailty
Objective: to investigate the relationship between functional class of orthostatic hypotension (FC OH) and frailty index (FI). Background: frailty syndrome (FS) as well as orthostatic…Comparative study of Non-Motor Symptoms and it’s correlation with Quality of Life in Parkinson’s disease and Atypical Parkinsonism
Objective: The present study aimed to evaluate and compare the non-motor symptoms and their correlation with quality of life in patients with PD and AP.…Efficacy and safety of adjunctive oral therapy in Parkinson’s disease with motor complications: a systematic review and network meta-analysis
Objective: To review the evidence and compare the efficacy and safety of catechol-O-methyltransferase inhibitors (COMT-Is), dopamine agonists (DAs) and monoamine-oxidase B inhibitors (MAOB-Is) as adjunctive…Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study – results of the Belgian subgroup
Objective: The primary objective of the study was to evaluate the proportion of Parkinson’s Disease (PD) patients in Movement Disorder Centers with Advanced Parkinson’s Disease…The Short Duration Response and Long Duration Response to L-Dopa are Needed to Restore Vigor-Motivation Coupling in Parkinson Disease
Objective: To assess the relationship between the Short Duration Response (SDR) and Long Duration Response (LDR) to L-Dopa therapy in Parkinson disease (PD) and restoration…Use of concomitant medications before and after treatment with levodopa/carbidopa intestinal gel in patients with advanced Parkinson’s disease: summary of phase 3 and real-world studies
Objective: Evaluate the use of concomitant Parkinson’s disease (PD) medications before and after treatment with levodopa/carbidopa intestinal gel (LCIG) using data from phase 3 clinical…Potentially inappropriate medication useage among patients newly diagnosed with dementia with Lewy bodies
Objective: Investigate the use of potentially inappropriate medications (PIM) among patients newly diagnosed with dementia with Lewy bodies (DLB). Background: PIM, including anticholinergics, are associated…
- « Previous Page
- 1
- …
- 108
- 109
- 110
- 111
- 112
- …
- 1374
- Next Page »